Thu 25 Jun 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| Efficacy and Safety Assessment of NIlotinib in Chronic Myeloid Leukemia (CML) Patients with Suboptimal Response on Imatinib Therapy (NISRI) | KAIMRC | Ongoing | NILOTINIB | 4 | RC12/052/R | King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam) |
| Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers, An International, Multicenter, Double Blind, Randomized Placebo Controlled Phase 3 trial (ICR-02/ASCOLT) | King Fahad Medical City | Ongoing | Aspirin | 3 | ICR-02/ASCOLT | King Fahad Medical City (Riyadh) |
| A study of the factors predicting radiation exposure to contacts of Saudi patients treated with radioactive iodine (I 131): A preliminary study for patients’ criteria selection for possible high dose I131 therapy on out-patient basis in the future | King Abdulaziz City for Science and Technology (KACST) | Completed | 131 Iodine | 4 | (version#1) dated 10-Apr-14 | King Abdullah Medical City (Makkah) |
| Middle East Observational Study in Metastatic Soft Tissue Sarcoma: An epidemiological study on the treatment patterns | Novartis | Ongoing | N/A | 4 | VEG201319 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| Prospective, multicentre, international Registry of male and female patients newly diagnosed with Atrial Fibrillation and treated with Rivaroxaban | Thrombosis Research Institute | Ongoing | Rivaroxaban | 4 | TRI08890 | Armed Forces Hospital (Southern Region) |
| (FLASH study)A 12-week treatment, multi-center, randomized, doubleblind,double-dummy, parallel group study to assess the efficacy and safety of switching fromsalmeterol/fluticasone to QVA149 (indacaterolmaleate/glycopyrronium bromide) in symptomatic COPD patients | Novartis | Ongoing | Ultibro breezhaler | 4 | A3405 V01 | King Fahad Medical City (Riyadh), King Fahad University Hospital (Al-Khobar), King Abdulaziz Medical City NG (Jeddah) |
| XALIA LEA- Xarelto® for Long-term and Initial Anticoagulation in VenousThromboembolism (VTE) in Latin America,EMEA and Asia | Bayer | Ongoing | Rivaroxaban | 4 | 17237 | King Fahad Medical City (Riyadh), King Fahad Hospital (Madinah), King Faisal Hospital (Taif), Hira Hospital (Makkah) |
| Prospective Multicentre Observational Registry Of Treatments And Outcomes In Patients With Chronic | Astellas Pharma International | Ongoing | N/A | 4 | ONC-MA1002 | Aseer Central Hospital |
| Early Goal Directed Sedation vs. Standard Care Sedation | The Australian and New Zealand Intensive Care Research Centre, Monash University, Australia | Ongoing | Dexmedetomidine | 4 | YS/003 | King Saud Medical City (Riyadh) |
| Efficacy of Different Mouthwashes in the Reduction of Halitosis: A Randomized, Double Blind, Placebo-Controlled, Crossover Clinical Trial | King Abdulaziz City for Science and Technology (KACST) | Ongoing | Halita - AO ProRinse | 4 | PR oo39 | College of Dentistry King Saud University |
Last update date: 08/05/2025 at 03:17 PM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.